Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Date:5/9/2008

Keryx to Host Investor Conference Call on Monday, May 12, 2008 at 8:30am

EDT

NEW YORK, May 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer, today announced its results for the first quarter ended March 31, 2008.

At March 31, 2008, the Company had cash, cash equivalents, investment securities, interest receivable and license receivable of $47.6 million, as compared to $64.7 million at December 31, 2007. In April 2008, we received a payment of $8.0 million that was classified as a license receivable at March 31, 2008. The payment was made pursuant to the September 2007 licensing agreement among Keryx, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

The net loss for the first quarter ended March 31, 2008 was $34,536,000, or $0.79 per share, compared to a net loss of $21,813,000, or $0.50 per share, for the first quarter in 2007, representing an increase in net loss of $12,723,000. The increase in net loss was primarily attributable to costs associated with the cessation of our development of Sulonex. Such costs included an $11,037,000 non-cash impairment charge related to the write-down of the assets of the Sulonex manufacturing suite to their estimated fair value, and a $2,063,000 provision for estimated costs relating to the required restoration of the manufacturing facility to its original condition, partially offset by a decrease of $2,264,000 in non-cash compensation expense, primarily related to stock options and restricted
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
(Date:5/20/2015)... 2015  Health eCareers, the healthcare industry,s online ... job seekers looking for the flexibility of short-term ... and online tool dedicated exclusively to temporary and ... SHIFT enables employers to quickly find and hire ... diem and other temporary positions, eliminating the time ...
(Date:5/20/2015)...  Cypher Genomics, Inc., a leading genome informatics ... to apply Cypher,s Coral TM technology to ... response to innovative medicines. The information generated from ... access to the right medicine at the right ... and potentially inform new companion diagnostics.  ...
(Date:5/20/2015)... CA, Mulhouse, France, Cambridge, MA (PRWEB) May 20, ... provider of high quality transporter assay services for ... and Pharmacology, and Rhenovia Pharma, a world leader ... neurotransmission using Translational Quantitative Systems Pharmacology supported by ... partnership agreement. , The agreement allows both companies ...
Breaking Biology Technology:Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... Nanotechnologies, Inc. ("Shrink") (OTC Markets: INKN), an innovative high ... binding letter of intent to acquire 100% of Hawaii-based ... with global distribution for its award-winning suites of life ... Shrink will exchange 25,750,000 shares of ...
... 11, 2011 Dyadic International, Inc. ("Dyadic") (OTC ... the discovery, development, manufacture and sale of enzyme ... and biopharmaceutical industries, today announced that its President ... at the Advanced Biofuels Leadership Conference taking place ...
... advancements of our electronic age rests on our ability ... to point B, through circuitry. Doing so requires particular ... solar cells, and that task falls to semiconductors. ... schools of Engineering and Applied Science and Arts and ...
Cached Biology Technology:Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 2Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 3Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 4Dyadic International to Present at Advanced Biofuels Leadership Conference 2Penn research advances understanding of lead selenide nanowires 2Penn research advances understanding of lead selenide nanowires 3
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... A University of California, Davis, microbiologist and a professional ... microbes to the International Space Station and study their ... Nov. 29 as winners of the International Space Station ... The team is led by Professor Jonathan Eisen ...
... 7. Dezember 2012 /PRNewswire/ -- Integrated Biometrics, LLC ... neuesten Fingerabdrucktechnologie einen weiteren technologischen Durchbruch bekannt. ... Produkt unter Verwendung der LES-Technologie (Light Emitting ... Film Transistor, TFT) her. Die LES-Technologie verwendet ...
... new plant-parasitic nematode worm ( Meloidoderita salina ) ... Michel Bay (MSMB) in France, where its abbey is a ... soil and is derived from the Latin word ,sal, or ... open source scientific journal ZooKeys . ...
Cached Biology News:Cheering microbes into space 2Integrated Biometrics stellt Sherlock vor - die weltweit leichtesten, dünnsten und kleinsten Appendix F Mobile ID-Fingerabdrucksensoren 2A pattern given by nature 2
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
...
... the first biological reagent that ... and not just by inhibiting ... anti-mycoplasma agent that can be ... directly. The cytotoxicity of Mynox ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: